CymaBay Therapeutics Inc. (CBAY) Reports Q4 Loss, Misses Revenue Estimates

1mon ago, source: Zacks.com on MSN

CymaBay Therapeutics Inc. (CBAY) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $0.30 per share a year ago.

CymaBay Therapeutics Inc CBAY

1mon ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

New Suit - Securities

1mon ago, source: Law

CymaBay Therapeutics and members of the company's board of directors were hit with a shareholder lawsuit on March 5 in Delaware District Court over the company's proposed acquisition by Gilead ...

Gilead (GILD) Gears Up to Report Q1 Earnings: What to Expect?

1d ago, source: Zacks.com on MSN

Gilead Sciences Inc. GILD is set to report first-quarter 2024 results on Apr 25, after market close. In the last reported ...

Maintaining Hold on CymaBay Amid Gilead Acquisition Deal Closure

1mon ago, source: Business Insider

Analyst Ed Arce of H.C. Wainwright maintained a Hold rating on CymaBay Therapeutics (CBAY – Research Report), with a price target of $32.50. Ed Arce has given his Hold rating due to a ...

Gilead Sciences Announces Completion of Acquisition of CymaBay

1mon ago, source: Stockhouse

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction to acquire CymaBay Therapeutics, Inc. (Nasdaq: CBAY) for approximately $4.3 billion in total ...

Gilead finalizes CymaBay acquisition to bolster liver disease treatments

1mon ago, source: Investing

FOSTER CITY, Calif. - Gilead Sciences, Inc. (NASDAQ:GILD) today completed its acquisition of CymaBay Therapeutics, Inc. (NASDAQ:CBAY) for a total equity value of approximately $4.3 billion. This ...

LCTX Lineage Cell Therapeutics, Inc.

1d ago, source: Seeking Alpha

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops ...